WuXi AppTec Completes First Phase Of $125 Million Biologics Manufacturing Facility

WuXi Biologics, a division of WuXi AppTec, a CRO/CMO, has completed construction of the first phase of a commercial-scale cGMP biologics perfusion manufacturing facility in Wuxi city, China. The entire project, announced in 2015, is expected to cost $150 million. The first phase includes two 1000L disposable bioreactors for perfusion processes. WuXi says the plant is the largest perfusion biologics manufacturing facility currently operating in Asia that uses disposable bioreactors.

Back to news